Approval · Notice of Compliance 29043 · 2022
PAXIL: Notice of Compliance 29043
Issued September 22, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 29043
- Date
- September 22, 2022
- Company
- Glaxosmithkline IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Safety Update to the Product Monograph (PM) and Package Insert
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| PAXIL | Not yet assigned | — |
Medicinal ingredients
- PAROXETINE HYDROCHLORIDE HEMIHYDRATE 10 MG per TAB
- PAROXETINE HYDROCHLORIDE HEMIHYDRATE 20 MG per TAB
- PAROXETINE HYDROCHLORIDE HEMIHYDRATE 30 MG per TAB